Can a drug combo make rectal cancer disappear before surgery?

NCT ID NCT07769853

NEW Not yet recruiting Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Aug 18, 2026 · Last updated Aug 18, 2026

Summary

This trial tests whether a combination of two investigational drugs (QL-1706) plus chemotherapy and bevacizumab, with or without radiation, can shrink or eliminate tumors in people with locally advanced rectal cancer before surgery. The goal is to see if this neoadjuvant approach can achieve a complete response—meaning no cancer is detectable after treatment. The study will also assess safety and whether skipping radiation is a viable option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iparomlimab and Tuvonralimab (QL-1706) combined with chemotherapy and bevacizumab, with or without radiotherapy
What this could lead to: If successful, this approach could shrink or eliminate rectal tumors before surgery, potentially allowing some patients to avoid radiation or even surgery, and improve long-term outcomes.
What could go wrong: This is an early-phase, single-arm trial, so results may not be confirmed in larger studies. The combination may cause significant side effects, and not all patients will respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for 5-12CM TO ANAL VERGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

5-12CM TO ANAL VERGE LOCALLY ADVANCED RECTAL CANCER (LARC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.